An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying targeted immunotherapies as a possible treatment for
recurrent meningioma. The names of the study interventions involved in this study are
nivolumab and ipilimumab.